Monica Vladut Talor

Monica Vladut Talor

Auto-generated profile, based on publicly available information

Monica Vladut Talor

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2015 in BMC Genomics
Verified
Journal Article
Open access
PDF file
LRLindsay M Reynolds
Lindsay M Reynolds
JDJingzhong Ding
Jingzhong Ding
JTJackson R Taylor
Jackson R Taylor
KLKurt Lohman
Kurt Lohman
NSNicola Soranzo
Nicola Soranzo
YLYongmei Liu
Yongmei Liu
Transcriptomic studies hold great potential towards understanding the human aging process. Previous transcriptomic studies have identified many genes with age-associated expression levels; however, small samples sizes and mixed cell types often make these results difficult to interpret. Using transcriptomic profiles in CD14+ monocytes from 1,264 participants of the Multi-Ethnic Study of Atherosclerosis (aged 55–94 years), we identified 2,704 genes differentially expressed with chronological age (false discovery rate, FDR ≤ 0.001). We further identified six networks of co-expressed genes that included prominent genes from three pathways: protein synthesis (particularly mitochondrial ribosomal genes), oxidative phosphorylation, and autophagy, with expression patterns suggesting these pathways decline with age. Expression of several chromatin remodeler and transcriptional modifier genes strongly correlated with expression of oxidative phosphorylation and ribosomal protein synthesis genes. 17% of genes with age-associated expression harbored CpG sites whose degree of methylation significantly mediated the relationship between age and gene expression (p < 0.05). Lastly, 15 genes with age-associated expression were also associated (FDR ≤ 0.01) with pulse pressure independent of chronological age. Comparing transcriptomic profiles of CD14+ monocytes to CD4+ T cells from a subset (n = 423) of the population, we identified 30 age-associated (FDR < 0.01) genes in common, while larger sets of differentially expressed genes were unique to either T cells (188 genes) or monocytes (383 genes). At the pathway level, a decline in ribosomal protein synthesis machinery gene expression with age was detectable in both cell types. An overall decline in expression of ribosomal protein synthesis genes with age was detected in CD14+ monocytes and CD4+ T cells, demonstrating that some patterns of aging are likely shared between different cell types. Our findings also support cell-specific effects of age on gene expression, illustrating the importance of using purified cell samples for future transcriptomic studies. Longitudinal work is required to establish the relationship between identified age-associated genes/pathways and aging-related diseases.

1 June 2003 in The Journal of Immunology
Verified
Journal Article
Open access
JBJobert G Barin
Jobert G Barin
MAMarina Afanasyeva
Marina Afanasyeva
MTMonica V Talor
Monica V Talor
NRNoel R Rose
Noel R Rose
CBC Lynne Burek
C Lynne Burek
PCPatrizio Caturegli
Patrizio Caturegli
The role of IFN-γ in the pathogenesis of autoimmune disease is controversial, being described as immunostimulatory in some studies and immunosuppressive in others. To determine the contribution of local expression of IFN-γ, we derived NOD.H-2h4 transgenic mice overexpressing IFN-γ in a thyroid-restricted manner. Transgenic mice, which had serum IFN-γ levels similar to wild-type littermates, showed up-regulation of MHC class II on thyrocytes, but did not develop spontaneous thyroiditis. Upon immunization with murine thyroglobulin, transgenic mice developed milder disease and reduced IgG1 responses compared with wild type. The milder disease was associated with decreased frequency of activated CD44+ lymphocytes in the cervical lymph nodes. This suppressive effect was confirmed by showing that blockade of systemic IFN-γ with mAb enhanced disease and increased IgG1 responses. The study supports a disease-limiting role of IFN-γ in autoimmune thyroiditis. Furthermore, it provides the first evidence that local IFN-γ activity in the thyroid is sufficient for disease suppression.

1 December 2024 in Circulation: Heart Failure
Verified
Journal Article
Open access
DLDiego Lema
Diego Lema
GJGabriel Jakobsson
Gabriel Jakobsson
ADAbdel Daoud
Abdel Daoud
DEDavid Elias
David Elias
MTMonica V. Talor
Monica V. Talor
DČDaniela Čiháková
Daniela Čiháková
BACKGROUND: Currently, there are no therapies targeting specific pathogenic pathways in myocarditis. IL (interleukin)-1 blockade has shown promise in preclinical studies and case reports. We hypothesized that blockade of IL1RAP (IL-1 receptor accessory protein), a shared subunit of the IL-1, IL-33, and IL-36 receptors, could be more efficient than IL-1 blockade alone. METHODS: We induced coxsackievirus B3 (CVB3)–mediated or experimental autoimmune myocarditis (EAM) in BALB/c mice, followed by treatment with an Fc (fragment crystallizable)-modified mIgG2a mouse anti-mouse IL1RAP monoclonal antibody (mCAN10). Myocarditis severity and immune infiltration were assessed by histology and flow cytometry. Cardiac function was measured by echocardiography. We used spatial transcriptomics (Visium 10× Genomics) to compare the gene expression landscape in the hearts of mCAN10-treated versus control mice. RESULTS: IL1RAP blockade reduced CVB3 and EAM severity. In EAM, the treatment prevented deterioration of cardiac function, measured on day 42 post-disease induction (left ventricular ejection fraction: 56.5% versus 51.0% in isotype controls [ P =0.002] and versus 51.4% in mice treated with anti-IL-1β antibodies alone [ P =0.003]; n=10–11 mice per group). In the CVB3 model, mCAN10 did not impede viral clearance from the heart and significantly lowered the numbers of CD4 + (cluster of differentiation 4) T cells ( P =0.025), inflammatory Ly6C + CCR2 + (lymphocyte antigen 6 complex, locus C/C-C motif chemokine receptor 2) monocytes ( P =0.038), neutrophils ( P =0.001) and eosinophils ( P <0.001) infiltrating the myocardium. The spatial transcriptomic analysis revealed reduced canonical IL-1 signaling and chemokine expression in cardiac immune foci in CVB3-infected mice treated with IL1RAP blockade. CONCLUSIONS: Blocking IL1RAP reduces acute CVB3 myocarditis and EAM severity and preserves cardiac function in EAM. We conclude that IL1RAP blockade is a potential therapeutic strategy in viral and autoimmune myocarditis.

1 March 2013 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
JMJean P. Molleston
Jean P. Molleston
WMWilliam Mellman
William Mellman
MNMichael R. Narkewicz
Michael R. Narkewicz
WBWilliam F. Balistreri
William F. Balistreri
RGRegino P. Gonzalez‐Peralta
Regino P. Gonzalez‐Peralta
PNPEDS‐C Clinical Research Network
PEDS‐C Clinical Research Network

5 May 2023 in Schizophrenia Research
Verified
Journal Article
Closed access
EDEmily C. Daniels
Emily C. Daniels
WEWilliam W. Eaton
William W. Eaton
DČDaniela Čiháková
Daniela Čiháková
MTMonica V. Talor
Monica V. Talor
HLHannah Lemke
Hannah Lemke
DKDeanna L. Kelly
Deanna L. Kelly

1 May 2012 in Thyroid®
Verified
Journal Article
Open access
Federica GuaraldiFederica Guaraldi
Federica Guaraldi
MLMelissa A. Landek-Salgado
Melissa A. Landek-Salgado
SHSusan Hutfless
Susan Hutfless
FSFrancesca Samoni
Francesca Samoni
MTMonica V. Talor
Monica V. Talor
PCPatrizio Caturegli
Patrizio Caturegli
Background: Pituitary antibodies have been reported with greater frequency in patients with Hashimoto's thyroiditis than in healthy controls, although there is significant variability in the strength of the association and the methodologies used. Methods: We designed a nested case–control study to characterize the prevalence of pituitary antibodies at the time of the clinical diagnosis of Hashimoto's thyroiditis, as well as at 2, 5, and 7 years before diagnosis. Active component female service member cases (n=87) and matched female controls (n=107) were selected using the Defense Medical Surveillance System database (DMSSD) between January 1998 and December 2007. Pituitary antibodies were measured by immunofluorescence using human pituitary glands collected at autopsy as the substrate. Results: At diagnosis, pituitary antibodies were present in 9% of cases with Hashimoto's (8 of 87) and 3% of controls (3 of 107). When the data were analyzed using a conditional logistic regression model, which takes into account the matching on age and work status, pituitary antibodies increased the odds of having Hashimoto's thyroiditis by sevenfold (95% confidence interval from 1.3 to 40.1, p=0.028), after adjusting for components of the DMSSD-category-termed race and for thyroperoxidase antibodies. Before diagnosis, pituitary antibodies were positive in 3 of the 11 subjects (2 cases and 1 control) at the −2-year time point, and negative in all 11 subjects at the −5- and −7-year time points. Conclusions: In summary, using a nested case–control design, we confirm that pituitary antibodies are more common in Hashimoto's thyroiditis and suggest that they appear late during its natural history.